Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority

RegulatoryISL/LENPositive

AI Analysis

Summary

Gilead and MSD are advancing ISL/LEN toward approval as a potential first-in-class once-weekly, single-tablet HIV treatment based on non-inferiority to standard of care.

Outcome Details

Pursuing approval based on non-inferiority to standard of care

Importance:6/10

Sentiment:

0.50

HIVonce-weeklysingle-tabletregulatory pathwaynon-inferiority

Related Companies

$GILD

Read the original article

Published by Clinical Trials Arena on July 22, 2026 11:51 AM

Read Original